HC Wainwright Issues Optimistic Estimate for VRDN Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Stock analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for Viridian Therapeutics in a research report issued on Thursday, August 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.28) for the quarter, up from their previous forecast of ($0.97). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($3.36) EPS, Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($1.26) EPS, Q3 2026 earnings at ($1.23) EPS, Q4 2026 earnings at ($1.29) EPS, FY2026 earnings at ($4.99) EPS, FY2027 earnings at ($2.92) EPS, FY2028 earnings at ($1.73) EPS and FY2029 earnings at $0.32 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same period in the prior year, the company posted ($0.81) earnings per share. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year.

Several other research analysts have also issued reports on the company. JMP Securities dropped their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group increased their price objective on Viridian Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday. Royal Bank Of Canada lowered their target price on Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating for the company in a research note on Thursday. Needham & Company LLC lowered their target price on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Finally, Oppenheimer raised their target price on Viridian Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock opened at $16.41 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.01 and a quick ratio of 11.01. The stock has a fifty day moving average price of $15.95 and a two-hundred day moving average price of $15.17. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $27.20. The firm has a market capitalization of $1.34 billion, a P/E ratio of -4.28 and a beta of 0.42.

Institutional Trading of Viridian Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank increased its position in Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after purchasing an additional 840 shares during the period. Foresite Capital Management VI LLC acquired a new stake in Viridian Therapeutics in the fourth quarter worth about $38,000. GAMMA Investing LLC increased its position in Viridian Therapeutics by 3,892.9% in the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after purchasing an additional 8,214 shares during the period. Summit Investment Advisors Inc. increased its position in Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock worth $147,000 after purchasing an additional 1,516 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Viridian Therapeutics in the second quarter worth about $170,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.